Loading organizations...

§ Private Profile · Milpitas, CA, USA
Medical device company developing automated insulin delivery systems and smart insulin pen caps integrating CGM data for diabetes.
Bigfoot Biomedical is a Milpitas, California-based medical device company that develops connected diabetes management technologies, including automated insulin delivery systems and smart insulin pen caps. The company's flagship Bigfoot Unity system integrates continuous glucose monitor data to provide real-time insulin dose recommendations for patients with type 1 and type 2 diabetes who require multiple daily injections. Prior to its acquisition, the healthtech firm raised over $250 million in venture capital funding from institutional backers such as Quadrant Capital Advisors and Abbott Laboratories. Following FDA clearance of its primary management system in May 2021, the business was fully acquired by Abbott in September 2023 to expand its connected health operations and integrate its services into a significantly larger medtech portfolio. Bigfoot Biomedical was founded in 2014 by Jeffrey Brewer, Bryan Mazlish, Lane Desborough, and Jon Brilliant.
Bigfoot Biomedical has raised $146.0M across 4 funding rounds.
Bigfoot Biomedical has raised $146.0M in total across 4 funding rounds.
Bigfoot Biomedical has raised $146.0M in total across 4 funding rounds.
Bigfoot Biomedical's investors include Abbott, Cormorant Asset Management, Janus Henderson Investors, Quadrant Capital Advisors, Joy Mashaal, Smile Group, Eclipse Ventures, JDRF T1D Fund, Senvest Management, T1D Exchange, Visionnaire Ventures, Visionaire Ventures.
Bigfoot Biomedical is a MedTech company that builds connected insulin-dosing systems—including the Bigfoot Unity connected insulin pen solution and automated insulin-delivery (closed‑loop) platforms—aimed at reducing the cognitive, emotional, and financial burden of insulin‑requiring diabetes by combining continuous glucose data, clinician instructions, and consumer-friendly hardware/software.[4][3]
High‑Level Overview
Origin Story
Core Differentiators
Role in the Broader Tech Landscape
Quick Take & Future Outlook
Quick take: Bigfoot transformed a patient‑driven engineering solution into a commercially oriented, clinically integrated diabetes platform that addresses a large, underserved segment (people on injections) and—through strategic partnerships and Abbott’s acquisition—has a real pathway to scale and wider clinical impact.[6][5][9]
Bigfoot Biomedical has raised $146.0M across 4 funding rounds. Most recently, it raised $55.0M Series C in June 2020.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jun 2, 2020 | $55M Series C | Abbott | Cormorant Asset Management, Janus Henderson Investors, Quadrant Capital Advisors, JOY Mashaal, Smile Group | Announced |
| Mar 1, 2018 | $18M Series B | — | Eclipse Ventures, Abbott, Cormorant Asset Management, Janus Henderson Investors, JDRF T1D Fund, Quadrant Capital Advisors, Senvest Management, T1D Exchange, Visionnaire Ventures | Announced |
| Dec 1, 2017 | $37M Series B | — | Eclipse Ventures, Visionaire Ventures | Announced |
| Oct 1, 2016 | $36M Series A | — | Eclipse Ventures, Visionaire Ventures | Announced |